Molecular alterations in indolent, aggressive and recurrent ovarian low-grade serous carcinoma

Abstract
 

Aims

The clinical course of patients with low-grade serous carcinoma (LGSC) can be substantially different. The purpose of this study was to explore whether molecular or pathological features could identify patients that follow a more aggressive course.

Conclusion

Despite limited case numbers, it appears that current molecular testing is inferior in predicting outcome of LGSCs compared to a pathological parameter or protein expression. Prediction of outcome based on the primary tumour may be confounded by additional acquired changes over time.